Workshop B — A Life Sciences Roadmap to Legal and Compliance in China: The Most Misunderstood Anti-Bribery, Trade, Blocking Statute, Data Security and Antitrust Requirements
Nathan Bush
Partner
DLA Piper (Singapore)
Leon C. G. Liu
Partner, Head of Government Enforcement and Investigations
JunHe LLP (China)
At this in-depth working group, you will benefit from a detailed review and assessment of critical changes affecting the legal and compliance landscape in China. Learn how life sciences companies are tailoring their compliance programs to the Chinese context and navigating known and unknown risk factors. In addition to speaker-prepared reference materials for your work, the workshop offers critical know-how for your business operations in China.
- A view from the ground – the latest legal developments and the most critical or common compliance risks
- Data protection and blocking statutes in China: Balancing these laws with DOJ and SEC expectations for FCPA compliance
- Evolving enforcement priorities on anti-bribery, penalty trends and key takeaways from local and international cases
- Status and key takeaways from recent sanctions cases — and practical tips for monitoring potential legislation and new sanctions targets
- How multinationals are evolving their programs in response to global trade tensions
- Revisiting gift, entertainment, hospitality and sponsorship policies
- Navigating the interplay of business and compliance pressures